FLT3 and acute myeloid leukemia: Preclinical studies demonstrated that both CD8+ and CD4+ T cells engineered to express FLT3-specific CARs exhibit potent cytotoxicity against AML cell lines and primary blasts expressing either wild-type or mutant FLT3 (87).